AbbVie (ABBV) – Credit Ratings
-
AbbVie (ABBV) upgraded to Baa1 at Moody's
-
S&P Downgrades AbbVie (ABBV) to 'A-' Amid Move to Acquire Stemcentrx; Outlook Stable
-
FDA Warnings on Viekira Pak are Credit-Negative for AbbVie (ABBV) - Moody's
-
Moody's Moves Outlook on AbbVie (ABBV) to Negative Following Review on Pharmacyclics (PCYC) Deal
-
S&P Revises Outlook on AbbVie (ABBV) to Negative Following Pharmacyclics (PCYC) News
-
S&P Affirms Raings on AbbVie (ABBV); Removes from CreditWatch Negative (SHPG)
-
S&P Places AbbVie (ABBV) on CreditWatch Negative Following Revised Shire (SHPG) Offer
-
S&P Lowers Outlook on AbbVie (ABBV) to Stable; Notes Willingness to Depart from Conservative Financial Policy
-
AbbVie's (ABBV) Potential Merger with Shire (SHPG) is Credit-Negative Event - Moody's
-
Moody's Lifts Outlook on AbbVie (ABBV) to Positive; Cites Expectations on Pipeline Execution
Back to ABBV Stock Lookup